Method for evaluating preventing effect of drug on viral pneumonia

Abstract

The invention relates to the technical field of drug evaluation and screening, discloses a method for establishing a pneumonia animal model, and provides a method for evaluating a preventing effect ofa drug on viral pneumonia by reasonably adopting the model to solve the problems that an existing pneumonia evaluation animal model is complex in modeling operation and not beneficial to subsequent evaluation and screening work of a pneumonia treatment drug. The pneumonia animal model is established by placing zebra fishes of 5dpf in water for culturing and injecting a pneumonia inducer poly(I:C)into the zebra fishes, wherein the administration concentration is greater than or equal to 50 ng per zebra fish; and indexes are evaluated by adopting the inflammatory regression effect, the macrophage improvement effect and the related gene RNA relative expression quantity effect during drug evaluation. The pneumonia model can be used for evaluating the toxicity or efficacy of known drugs can be further used for screening unknown drugs, the real situation of the drugs in vivo can be accurately reflected, in-vivo high-throughput screening or evaluating of the treatment effect of the drugs onviral pneumonia can be realized, and the advantages of reliability, rapidness, high efficiency, low cost, high cost performance and the like are achieved.

Description

technical field [0001] The invention relates to the technical field of drug evaluation and screening, in particular to a method for evaluating the effect of drugs on preventing viral pneumonia. Background technique [0002] In non-bacterial pneumonia, viral pneumonia accounts for 25%-50%, and it is often aspiration infection. The main source of infection is the patient. It is transmitted through droplets and close contact. It occurs in eruptive viral infection, often accompanied by trachea-bronchial infection, mostly occurs in winter and spring, can be sporadic or popular, and is more common in infants, the elderly, and patients with existing chronic cardiopulmonary diseases. Among them, influenza virus is the most common pathogen of viral pneumonia in adults and the elderly, while viral pneumonia in infants and young children is often caused by respiratory syncytial virus infection. Others such as parainfluenza virus, cytomegalovirus, coronavirus, adenovirus, rhinovirus an...

AI Technical Summary

Problems solved by technology

Moreover, an ideal experimental animal model of pneumonia should be able to replicate the mechanism and consequences of human pneumonia, but so far no experimental animal model can completely replicate all the characteristics of human pneumonia. The pathophysiological characteristics can be replicated, such as abnormal ventilation function, decreased lung compliance, lung parenchymal injury and increased alveolar capillary membrane permeability, etc., and these animal models have complicated modeling operations, high technical requirements, and large surgical trauma. , low incidence of pneumonia, high complications and mortality, unstable model establishment, poor reproducibility, etc., long experimental cycle, high cost, and heavy workload, which are not conducive to the evaluation and screening of subsequent pneumonia treatment drugs

Others, such as in vitro cell models, lack the metabolic transformation of the drug in the whole organism and the circulation distribution in the body, and cannot reflect the real situation of the drug in the body

Images